Pharmacogenetic studies of OCD have focused on the role of common genetic variants in treatment response (41). However, to date, no replicated significant GWAS variant has been reported for OCD - likely due to the small sample sizes - and therefore it has been challenging to contextualize the results of pharmacogenetic studies. Future studies examining predictors of treatment response will shift the focus from select common genetic variants to genome-wide studies that also estimate how rare and common risk variants jointly affect liability and optimal interventions (42).
